| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
Cyclin-dependent kinases (CDKs), including CDK3, CDK4, CDK5, CDK6, CDK7, and CDK8. CDKs play specific roles in the progression of the cell cycle. Inhibition of CDKs blocks cell cycle progression and induces apoptosis in cancer cells.
|
|---|---|
| ln Vitro |
Individual CDKs, including CDK1, CDK2, CDK3, CDK4, CDK5, CDK6 and CDK7, CDK8, and so on, can be categorized as G1, S, or G2M phase enzymes and play specific roles in the advancement of the cell cycle. Cancer cells are known for their unchecked proliferation, and many significant solid tumors frequently have CDK function misregulation[1].
CDK-IN-6 exhibits potent anticancer activities as a CDK inhibitor. It inhibits CDK3, CDK4, CDK5, CDK6, CDK7, and CDK8, which are involved in cell cycle regulation. Detailed IC₅0 values against specific CDK isoforms have not been reported in available literature. |
| ln Vivo |
No detailed in vivo activity data has been reported for CDK-IN-6. As a CDK inhibitor with anticancer activity, it could potentially be evaluated in mouse xenograft models of various cancers, but specific in vivo data are not available.
|
| Enzyme Assay |
CDK inhibition assays: CDK-IN-6 is incubated with purified CDK/cyclin complexes and a substrate peptide in the presence of ATP. Kinase activity is measured by detecting substrate phosphorylation using radiometric or luminescent methods. IC₅0 values against various CDK isoforms are calculated from dose-response curves.
|
| Cell Assay |
Cancer cell lines (e.g., breast, lung, colon, or leukemia cell lines) are treated with CDK-IN-6. Cell viability is measured using MTT or CellTiter-Glo assays. Cell cycle analysis is performed by flow cytometry. Apoptosis is evaluated by Annexin V/PI staining. CDK substrate phosphorylation is assessed by Western blot to confirm target engagement.
|
| Animal Protocol |
Mouse xenograft models bearing human tumor cell lines could be used to evaluate CDK-IN-6 in vivo. The compound would be administered orally or intraperitoneally, and tumor growth inhibition would be assessed. Pharmacodynamic markers (CDK substrate phosphorylation) would be measured in tumor tissues.
|
| ADME/Pharmacokinetics |
CDK-IN-6 has a molecular weight of 380.49 and a molecular formula of C21H2₈N₆O. It is a pyrazolo[1,5-a]pyrimidine compound. Detailed pharmacokinetic parameters have not been reported.
|
| Toxicity/Toxicokinetics |
No toxicity data has been published for CDK-IN-6. As a research compound, it is not intended for human therapeutic use. Its selectivity and potency make it an important tool for studying cell cycle regulation and targeted anticancer therapies.
|
| References | |
| Additional Infomation |
CDK-IN-6 is a pyrazolo[1,5-a]pyrimidine CDK inhibitor with anticancer activities. It inhibits CDK3, CDK4, CDK5, CDK6, CDK7, and CDK8. It is used in preclinical studies to explore CDK-driven oncogenic pathways. The compound is for research use only and has not entered clinical trials.
|
| Molecular Formula |
C21H28N6O
|
|---|---|
| Molecular Weight |
380.49
|
| Exact Mass |
380.232
|
| CAS # |
779353-02-5
|
| PubChem CID |
25234813
|
| Appearance |
Light yellow to brown solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Index of Refraction |
1.673
|
| LogP |
2.9
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
28
|
| Complexity |
480
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CCC1=C2N=C(C=C(N2N=C1)NCC3=CN=CC=C3)N4CCCC[C@H]4CCO
|
| InChi Key |
FWKFUJKFJMIJDX-SFHVURJKSA-N
|
| InChi Code |
InChI=1S/C21H28N6O/c1-2-17-15-24-27-19(23-14-16-6-5-9-22-13-16)12-20(25-21(17)27)26-10-4-3-7-18(26)8-11-28/h5-6,9,12-13,15,18,23,28H,2-4,7-8,10-11,14H2,1H3/t18-/m0/s1
|
| Chemical Name |
2-[(2S)-1-[3-ethyl-7-(pyridin-3-ylmethylamino)pyrazolo[1,5-a]pyrimidin-5-yl]piperidin-2-yl]ethanol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 50 mg/mL (131.41 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.57 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6282 mL | 13.1409 mL | 26.2819 mL | |
| 5 mM | 0.5256 mL | 2.6282 mL | 5.2564 mL | |
| 10 mM | 0.2628 mL | 1.3141 mL | 2.6282 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
